E-Mail 'Gefitinib Offers Modest Results in Esophageal Ca' To A Friend

Email a copy of 'Gefitinib Offers Modest Results in Esophageal Ca' to a friend

* Required Field






Separate multiple entries with a comma. Maximum 5 entries.



Separate multiple entries with a comma. Maximum 5 entries.


E-Mail Image Verification

Loading ... Loading ...
VIENNA (MedPage Today) -- Treatment with gefitinib, a targeted EGFR inhibitor, failed to improve survival in advanced esophageal cancer but did slow disease progression, according to a study reported here.

Gefitinib Offers Modest Results in Esophageal Ca

VIENNA (MedPage Today) — Treatment with gefitinib, a targeted EGFR inhibitor, failed to improve survival in advanced esophageal cancer but did slow disease progression, according to a study reported here.